Premium
Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration
Author(s) -
Sin J. H.,
Elshaboury R. H.,
Hurtado R. M.,
Letourneau A. R.,
Gandhi R. G.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12630
Subject(s) - ethambutol , medicine , pyrazinamide , therapeutic drug monitoring , levofloxacin , intensive care medicine , tuberculosis , renal replacement therapy , hemofiltration , mycobacterium tuberculosis , amikacin , pharmacokinetics , pharmacology , hemodialysis , surgery , antibiotics , pathology , microbiology and biotechnology , biology
Summary What is known and objective There is a lack of data regarding therapeutic drug monitoring ( TDM ) of antitubercular agents in the setting of continuous venovenous haemofiltration ( CVVH ). We describe TDM results of numerous antitubercular agents in a critically ill patient during CVVH and haemodialysis. Case summary A 49‐year‐old man was initiated on treatment for disseminated Mycobacterium tuberculosis . During hospital admission, the patient developed critical illness and required renal replacement therapy. TDM results and pharmacokinetic calculations showed adequate serum concentrations of rifampin, ethambutol and amikacin during CVVH and of rifampin, pyrazinamide, ethambutol and levofloxacin during intermittent haemodialysis. What is new and conclusion The presence of critical illness and renal replacement therapy can induce pharmacokinetic changes that may warrant vigilant TDM to ensure optimal therapy. To our knowledge, this is the first report to describe TDM for several antitubercular agents during CVVH in a critically patient with disseminated M. tuberculosis .